Effects of sirolimus on Lung function in patients with Lymphangioleiomyomatosis
Background: Lymphangioleiomyomatosis (LAM) is a progressive lungs disease that affects women at reproductive years. Sirolimus inhibits mammalian target of rapamycin (mTOR) and its administration in past studies was hopeful in treatment of patients with LAM. The aim of this study was to evaluate siro...
Main Authors: | Fatemeh Aghaeimeybodi, katayoun Najafizadeh, seid kazem razavi ratki, nasim namiranian |
---|---|
Format: | Article |
Language: | English |
Published: |
Babol University of Medical Sciences
2019-01-01
|
Series: | Caspian Journal of Internal Medicine |
Subjects: | |
Online Access: | http://caspjim.com/browse.php?a_code=A-10-1041-1&slc_lang=en&sid=1 |
Similar Items
-
Long-term efficacy and safety of sirolimus therapy in patients with lymphangioleiomyomatosis
by: Siqi Hu, et al.
Published: (2019-08-01) -
Functional improvements in patients with lymphangioleiomyomatosis after sirolimus: an observational study
by: Yongzhong Zhan, et al.
Published: (2018-02-01) -
Pulmonary lymphangioleiomyomatosis presenting as spontaneous pneumothorax treated with sirolimus - A case report
by: Ajay Kumar Verma, et al.
Published: (2018-01-01) -
Efficacy and safety of low-dose Sirolimus in Lymphangioleiomyomatosis
by: Hee-Young Yoon, et al.
Published: (2018-11-01) -
Efficacy of sirolimus for the prevention of recurrent pneumothorax in patients with lymphangioleiomyomatosis: a case series
by: Li Zhou, et al.
Published: (2018-09-01)